



CLERMONT-FERRAND
CENTRE HOSPITALIER UNIVERSITAIRE


Pascal Motreff, MD, PhD



UNIVERSITÉ
Clermont
Auvergne

CARDIO
RUN
2023

15^{eme} CONGRÈS
DE PATHOLOGIE
CARDIO-VASCULAIRE




*Spécificité de la
coronaropathie du sujet âgé*

Définition du sujet âgé :

- 10 ans de plus que son patron ?


Définition du sujet âgé :

- 10 ans de plus que son patron ?
- Plus de 65 ans ?



Définition du sujet âgé :

- 10 ans de plus que son patron ?
- Plus de 65 ans ?
- Plus de 75 ans ?
- Plus de 80 ans ?



22% des SCA ST+
14% des SCA ST+



33% des PCI
20% des PCI

Pathologie d'avenir...

x 2 octogénaires en 2040
(7 millions)



Coronary disease CORONARY INTERVENTIONS IN THE ELDERLY

Jan Kaehler, Thomas Meinertz, Christian W Hamm

1167

aged 65 years

Heart 2006;92:1167-1171. doi: 10.1136/hrt.2005.071266

Take the online multiple choice questions associated with this article (see page 1171)


Cardiovascular disease (CVD) is the leading cause of morbidity, mortality, and reduced quality of life in western cultures. Elderly patients, usually defined as those aged 65 years or above, are particularly affected, since they are the fastest growing segment of the population, the absolute prevalence of CVD will therefore increase further. Among cardiovascular diseases, coronary artery disease is—by quantity and quality—the most prominent one, a fact that emphasises the relevance of coronary interventions in these patients.

Coronaropathie du sujet âgé


Sujet âgé



Coronaropathie dégénérative, FRCV



> 85 ans



Pyramide des âges en France en 2021
et projection pour 2070

Espérance de vie :

79 ans pour Hommes

85 ans pour Femmes


Population de plus de 85 ans :

= 1.8 Million

= 5.0 Millions en 2050


Vieillesse artérielle

Augmentation du calibre
des gros vaisseaux




Tortuosités

- Allongement vasculaire
- *Tassement squelettique*



Remaniement de la paroi
Athérosclérose / Artériosclérose


Dysfonction endothéliale
Remodelage matrice extracellulaire
↳ fibres élastiques ↗ collagène
Calcifications pariétales



→ Paroi devient plus rigide

Coronaropathie du sujet âgé




Coronarien



Sujet âgé



Progrès de la médecine, de la cardiologie



- **Syndrome coronarien chronique (2019)**

 **ESC**
European Society
of Cardiology

European Heart Journal (2023) **00**, 1–107
<https://doi.org/10.1093/eurheartj/ehad191>

ESC GUIDELINES

2023 ESC Guidelines for the management of acute coronary syndromes

| | |
|--|-----|
| 8.2 Non-cardiovascular comorbidities | 451 |
| 8.2.1 Cancer | 451 |
| 8.2.2 Diabetes mellitus | 451 |
| 8.2.3 Chronic kidney disease | 452 |
| 8.2.4 Elderly | 452 |

- **Syndrome coronarien aigu (2023)**

 **ESC**
European Society
of Cardiology

European Heart Journal (2020) **41**, 407–477
[doi:10.1093/eurheartj/ehz425](https://doi.org/10.1093/eurheartj/ehz425)


ESC GUIDELINES



2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

| | |
|--|----|
| 12.3.3. Diabetes mellitus | 60 |
| 12.3.4. Older adults with frailty and multimorbidity | 60 |
| 12.3.4.1. The older person | 60 |
| 12.3.4.2. Frailty and multimorbidity | 60 |
| 12.3.5. Pregnancy | 61 |
| 12.3.6. Drug abuse | 61 |
| 12.3.7. Patients with cancer | 61 |
| 12.3.8. Coronavirus disease (COVID-19) | 61 |

Coronaropathie du sujet âgé



Coronaropathie du sujet âgé

Patient fragile

Fonctions cognitives

Activités, gêne fonctionnelle

Sarcopénie

Comorbidités

Espérance de vie

Décision difficile, à partager

Heart Team, avis gériatrique

Procédures complexes et à haut risque

Lésions critiques : TC, pluritronculaires

Lésions résistantes (calcifications)

Difficultés techniques (abords, tortuosités, CTO)

Comorbidités cardiaques (TAVI, dysfonction VG)

Comorbidités extracardiaques (I.Rénale, I.Respi)

Alternatives ou Rescue déraisonnables (pontages, assistance)

Environnement pharmacologique

Haut risque ischémique et hémorragique

Prévention



Primary prevention in **older people**:
It's never too late to initiate risk factor management strategies



Quit smoking



Manage dyslipidemia with
shared decision-making



Treat hypertension.
Individualize target BP



Aspirin may have a poor
benefit:risk ratio



Eat a healthy diet



Tailored, increase in
physical activity level




Individualized risk/benefit analysis: Consider comorbidities,
frailty, competing (non-CV) risks, life expectancy, and patient
preferences



Multidisciplinary-team approach


Eur J Preventive Cardiol 2022

 **ESC** European Society of Cardiology
European Journal of Preventive Cardiology (2022) 29, 1412–1424
<https://doi.org/10.1093/eurjpc/zwac033> **REVIEW**

**Cardiovascular disease in the elderly:
proceedings of the European Society of
Cardiology—Cardiovascular Round Table**


Coronaropathie du sujet âgé

Prévention



Lifetime benefit of preventive risk factor treatment

+




Treatment decision

Eur J Preventive Cardiol 2022

Prévention

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Lancet 2019



Interpretation Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older than 75 years who do not already have evidence of occlusive vascular disease. This limitation is now being addressed by further trials.

Syndrome coronarien chronique : SCC

Après 75 ans :

Prévalence coronaropathie élevée

Morbi-mortalité plus élevée (âge, comorbidités)

Sous-représentée dans les études

Sous-traitée, sous-diagnostiquée

Symptômes atypiques, masqués par comorbidités

Test de dépistages limités (imagerie de stress, coroscanner)

➔ **retard diagnostic**



SCC

Après 75 ans :**Options thérapeutiques :**attention aux risques hémorragiques, IR,
complications neuro, site ponctionDES recommandé
DAPT plus courte**Recommendations for elderly patients with chronic coronary syndromes**

| Recommendations | Class ^a | Level ^b |
|--|--------------------|--------------------|
| It is recommended that particular attention is paid to side effects of drugs, intolerance, and overdosing in elderly patients. | I | C |
| The use of DES is recommended in elderly patients. ^{508,509} | I | A |
| Radial access is recommended in elderly patients to reduce access-site bleeding complications. ^{506,507} | I | B |
| It is recommended that diagnostic and revascularization decisions are based on symptoms, the extent of ischaemia, frailty, life expectancy, and comorbidities. | I | C |

Décision

When, who, and how to perform revascularization

Myocardial revascularization should be performed to improve prognosis or symptoms as recommended in the 2018 ESC/EACTS Guidelines on myocardial revascularization (Table 2).⁸⁹ Shared decision-making should include consultation with a heart team,

Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology—Cardiovascular Round Table

Lettino M, Eur J Preventive Cardiol 2022

Table 2 Summary of extent of disease indicating a need for revascularization in patients with stable CAD and documented ischaemia or a haemodynamically relevant lesion from the 2018 European guidelines on myocardial revascularization

Goal of improving prognosis

- >50% stenosis in
 - Left main CAD
 - Proximal left anterior descending CAD
 - 2- or 3-vessel disease with LVEF \leq 35%
 - Sole remaining patent coronary artery
- Extensive ischaemia on functional testing (>10% LV) or abnormal invasive fractional flow reserve

Goal of improving symptoms

- Haemodynamically significant stenosis in patients with limiting angina on optimized medical therapy

Prise en compte du sur-risque

EXPERT PANEL


GERIATRIC CARDIOLOGY

Assessment and Management of Older Adults Undergoing PCI, Part 1

A JACC: Advances Expert Panel

Nanna MG, JACC Adv 2023

CENTRAL ILLUSTRATION Definitions of a Variety of Geriatric Syndromes Likely Influencing the Individual Risk of Older Adults Undergoing Percutaneous Coronary Intervention



Coronaropathie du sujet âgé



THE PRESENT AND FUTURE

JACC STATE-OF-THE-ART REVIEW

Interventions for Frailty Among Older Adults With Cardiovascular Disease

JACC State-of-the-Art Review

CENTRAL ILLUSTRATION Interventions Aimed at Preventing or Reversing Frailty in Patients With Cardiovascular Disease



HIGHLIGHTS

- Physical frailty syndrome is associated with poor outcomes after cardiovascular events.
- The etiology of frailty in older adults is multifactorial and patient specific.
- Multimodal interventions, including cardiac rehabilitation, can reduce frailty.

Coronaropathie du sujet âgé

SCC

Lésions proximales, complexes, calcifiées

Progrès ces 15 dernières années +++ : TC, bifurcations ,CTO
Rotablator, Shockwave, Orbital
Accompagnement TAVI

Coronaropathie du sujet âgé

SCC

Lésions proximales, complexes, calcifiées

Progrès ces 15 dernières années +++ : TC, bifurcations ,CTO

Rotablator, Shockwave, Orbital
Accompagnement TAVI

Cas de Mme E. 94 ans

autonome, angor extrêmement serré, pas de comorbidité
très demandeuse

Coronaropathie du sujet âgé

Cas de Mme E., 94 ans


Angor d'effort serré





Cas de Mme E., 94 ans

- 7 guides
- 1 microcatheter
- 1 extension catheter
- 1 fraise **Rotablator**
- 4 Stents (DES)




Coronaropathie du sujet âgé

Cas de Mme M., 89 ans




ATCD radiothérapie thoracique
Angor, Coro pré TAVI




Calcifications superficielles
circonférentielles sur long
segment IVA proximale





Bourgeon calcifiée fin de TC



Coronaropathie du sujet âgé



Rotablator,
Prédilatation NCB,
Stenting TC, Stenting IVA,
REPOT



Syndrome coronarien aigu : SCA



ESC

European Society
of Cardiology

European Heart Journal (2020) 00, 1–79
doi:10.1093/eurheartj/ehaa575

ESC GUIDELINES

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Eur Heart J 2020

| Recommendations | Class ^a | Level ^b |
|---|--------------------|--------------------|
| It is recommended to apply the same diagnostic strategies in older patients as for younger patients. ⁴⁵⁸ | I | B |
| It is recommended to apply the same interventional strategies in older patients as for younger patients. ^{463,467} | I | B |
| The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as specific contraindications. ⁴⁶¹ | I | B |

Syndrome coronarien aigu : SCA

Plus de 75 ans :

Proportion croissante

Exclus ou sous-représentés dans les études

Age = facteur de risque de morbi-mortalité +++

Troponine US très performante même si davantage de « faux positifs »

- **NSTEMI** : peu d'études consacrées > 80 ans : attitude plutôt invasive, mais individualisée (EVAOLD)
- **STEMI** : angioplastie primaire doit être proposée (si raisonnable), voire fibrinolyse



ESC

European Society
of Cardiology


European Heart Journal (2023) 00, 1–107
<https://doi.org/10.1093/eurheartj/ehad191>

ESC GUIDELINES


2023 ESC Guidelines for the management of acute coronary syndromes

Byrne RA, Eur Heart J 2023

Données France PCI (2014-2022)



Données France PCI (2014-2022)



SCA

RA Byrne, *Eur Heart J* 2023

Lien entre **syndrome gériatrique** (fragilité + comorbidités) et pronostic


| Older adults | | |
|---|---|---|
| It is recommended to apply the same diagnostic and treatment strategies in older patients as in younger patients. ^{662,664,665,710,711} | I | B |
| It is recommended to adapt the choice and dosage of antithrombotic agent, as well as of secondary prevention medications, to renal function, co-medications, comorbidities, frailty, cognitive function, and specific contraindications. ^{363,712} | I | B |
| For frail older patients with comorbidities, a holistic approach is recommended to individualize interventional and pharmacological treatments after careful evaluation of the risks and benefits. ^{668,673,676} | I | B |

SCA

Circulation

AHA SCIENTIFIC STATEMENT

Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association



Contemporary Revascularization Dilemmas in Older Adults

Sonali Kumar, MD; Michael McDaniel, MD; Habib Samady, MD; Farshad Forouzandeh, MD, PhD

S. Kumar, JAHA 2020

Specific Consideration Regarding Obstructive CAD in Older Adults

Importance

Older adults many times do not receive evidence-based, especially life-saving interventions for obstructive CAD, due to the lack of knowledge, confidence, and data

ACS Presentation

Older adults commonly have atypical symptoms such as atypical chest pain, nausea, vomiting, generalized weakness as presenting symptoms of ACS leading to delay in timely diagnosis

ACS Management

Despite increased prevalence of high risk features such as heart failure, diabetes, and higher GRACE scores in the elderly, invasive procedures are not offered to many older adults while evidence show that many of them can benefit from such procedures even when presenting with cardiogenic shock.

Stent type

Studies suggest, among elderly, DESs should be the preferred over BMSs even if short duration of DAPT is desired for specific reasons, i.e. bleeding risks.

Concomitant Anticoagulation

Due to increased prevalence of AF in older age, need for long-term anticoagulation is common at this age group. However, limited data is available for the best strategy of concomitant DAPT and anticoagulation. While no guideline or FDA recommendation exist, most clinicians use short duration of triple therapy, such as 2-4 weeks, and then stop aspirin and continue with a P2Y12 inhibitor, mostly clopidogrel, and a direct oral anticoagulant.

Concomitant severe AS

The timing of PCI in relation to TAVR remains largely unclear. In one study, FFR-guided PCI prior to TAVR showed better outcome than medical therapy alone or angiographic-guided PCI.

Future Directions

Reporting safety results (to determine benefits and risk), conduction of trials exclusively including elderly patients only, and a better understanding of the frailty and cognitive impairment that affects this high-risk population will improve the enrollment rates of elderly in clinical trials and hence the care for older adults with obstructive CAD.

Coronaropathie du sujet âgé

SCA

Evaluation de la fragilité patient **difficile en phase aiguë**

Responsabilité urgentiste/ SAMU

Bénéfice de la revascularisation indiscutable : **utile ou futile ?**



Coronaropathie du sujet âgé

recommandations à l'épreuve du quotidien

Retour de congés Aout 2023



- **Dossier sur bureau confié par chirurgien**

Mr B., 99 ans, ATCD de pontages réseau gauche à 85 ans, angor très serré subocclusion ostiale CD, patient et famille très demandeurs


- **Première astreinte du WE, 1h du matin**

Mme F. 92 ans, obèse, autonome à domicile, SCA ST+ inférieur, BAV complet, hémodynamique instable



Coronaropathie du sujet âgé

Cas de Mme F. 92 ans

SCA ST+ inférieur, BAV, Killip 3



Coronaropathie du sujet âgé




Cas de Mr B. 99 ans


Ponté à 85 ans, reprend un AE serré



Coronaropathie du sujet âgé



Cas de Mr B. 99 ans



Coronaropathie du sujet âgé

Take Home Message

- Idéalement **même prise en charge** que l'ensemble de la population... mais **patients plus fragiles, procédures plus complexes**



- Evaluer la balance bénéfique/risque
- Nécessité d'informer le patient et les proches du surrisque
- Formation aux procédures complexes et à la gestion des complications

Coronaropathie du sujet âgé

Take Home Message



« Il ne faut pas ajouter
des années à la vie,
il faut ajouter
de la vie aux années. »

- André Malraux